Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Accured Expenses: 2021-2025

Historic Change in Accured Expenses for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$274,066.

  • InMed Pharmaceuticals' Change in Accured Expenses rose 57.34% to -$274,066 in Q3 2025 from the same period last year, while for Sep 2025 it was $118,598, marking a year-over-year increase of 442.51%. This contributed to the annual value of -$249,728 for FY2025, which is 651.50% down from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Change in Accured Expenses is -$274,066, which was down 4,946.33% from -$5,431 recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Change in Accured Expenses peaked at $765,664 during Q4 2021, and registered a low of -$642,392 during Q3 2024.
  • In the last 3 years, InMed Pharmaceuticals' Change in Accured Expenses had a median value of -$76,470 in 2023 and averaged -$70,561.
  • Per our database at Business Quant, InMed Pharmaceuticals' Change in Accured Expenses slumped by 253.19% in 2023 and then soared by 312.82% in 2024.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Change in Accured Expenses stood at $765,664 in 2021, then plummeted by 145.66% to -$349,611 in 2022, then skyrocketed by 169.04% to $241,378 in 2023, then soared by 48.98% to $359,614 in 2024, then spiked by 57.34% to -$274,066 in 2025.
  • Its Change in Accured Expenses was -$274,066 in Q3 2025, compared to -$5,431 in Q2 2025 and $38,481 in Q1 2025.